Lexeo Therapeutics (NASDAQ:LXEO) has reported interim Phase I/II clinical trial results for LX2020, its investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), alongside an update on discussions with the US Food and Drug Administration regarding a potential accelerated approval pathway.
The company said participants receiving higher doses of LX2020 demonstrated a mean reduction of 80% in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions at their latest assessments.
Lexeo also reported a third-quarter 2026 net loss of $38.3 million, compared with $20.3 million a year earlier, while its cash and investment balance stood at $219.1 million at the end of September.
The clinical and financial updates were disclosed on November 16, 2026.
The ongoing HEROIC-PKP2 Phase I/II study is evaluating LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy, an inherited heart condition associated with abnormal heart rhythms.
According to Lexeo, participants in the higher-dose treatment cohorts demonstrated reductions in measures of ventricular arrhythmia burden.
At the latest assessment, the mean reduction in NSVT was 80%, while premature ventricular contractions declined by an average of 44%.
Six of the seven participants in the high-dose cohorts showed improvement in NSVT measurements.
The company also reported that five of the seven participants demonstrated symptom improvement based on a patient-reported outcome measure.
As of the October 15, 2026 data cutoff, 10 participants had received LX2020, with nine completing at least 12 months of follow-up.
The findings provide preliminary evidence of changes in arrhythmia measurements following treatment, although the study remains ongoing and involves a limited number of participants.
Lexeo said LX2020 was generally well tolerated across the 10 participants treated in the HEROIC-PKP2 study.
No clinically significant complement activation was observed, and no participant discontinued the trial.
The company reported that previously disclosed elevations in liver function tests among participants receiving higher doses were managed according to the study protocol.
One previously reported Grade 3 serious adverse event involving ventricular tachycardia occurred approximately three months after dosing.
The event was treated with anti-arrhythmic medication.
Lexeo did not report additional treatment discontinuations in the latest interim analysis.
The safety findings remain preliminary, with further monitoring required to assess longer-term outcomes as the clinical programme progresses.
Lexeo also provided an update on its regulatory discussions with the US Food and Drug Administration concerning the development of LX2020.
According to the company, the FDA indicated openness to using guideline-defined non-sustained ventricular tachycardia as the primary surrogate endpoint in a pivotal clinical study designed to support accelerated approval.
The accelerated approval pathway allows certain treatments for serious conditions to be considered for approval based on surrogate endpoints that are reasonably likely to predict clinical benefit.
However, the FDA’s indicated openness to the proposed endpoint does not constitute agreement on a final study design or guarantee regulatory approval.
Lexeo expects to finalise the design of its pivotal LX2020 study during the first half of 2027.
The company is targeting initiation of the study in the second half of 2027, subject to regulatory alignment and clinical development progress.
Alongside the clinical update, Lexeo reported its financial results for the third quarter ended September 30, 2026.
The company recorded a net loss of $38.3 million, equivalent to $0.43 per share, compared with a net loss of $20.3 million, or $0.33 per share, in the corresponding period of 2025.
Research and development expenses increased to $34.5 million from $15.7 million a year earlier.
Lexeo attributed part of the increase to costs associated with its acquisition of Mantle Therapeutics, which was completed in September 2026.
General and administrative expenses were $5.9 million, remaining approximately unchanged from the prior-year period.
The higher research and development expenditure contributed to the widening of the quarterly net loss.
Lexeo ended September 2026 with cash, cash equivalents and investments of $219.1 million.
The company stated that its available financial resources are expected to support operations into 2028.
This projected funding period covers the planned finalisation and initiation of the LX2020 pivotal study during 2027.
The cash runway estimate remains dependent on future expenditure, clinical development activities and other operating requirements.
Lexeo did not provide revised full-year revenue or earnings guidance in the announcement.
Lexeo also announced the appointment of Toby Schilke as an independent director.
Schilke previously served as chief financial officer of Crinetics Pharmaceuticals.
The appointment adds financial and biotechnology industry experience to Lexeo’s board as the company continues developing its clinical programmes.
The announcement did not specify additional changes to the company’s executive management structure.
Lexeo’s next planned regulatory and clinical milestones centre on finalising the LX2020 pivotal study design in the first half of 2027 and beginning the trial during the second half of the year.
The interim HEROIC-PKP2 findings showed reductions in ventricular arrhythmia measurements among higher-dose recipients, while the company reported no treatment discontinuations across the 10 participants studied.
Nevertheless, the limited patient population and ongoing nature of the study mean that additional evidence will be required to establish the treatment’s safety and efficacy.
LX2020 remains investigational, and any accelerated approval application would depend on the results of further clinical development and regulatory review.
Lexeo Therapeutics stock price
| 55 min | |
| 1 hour | |
| 2 hours | |
| Nov-15 | |
| Nov-02 | |
| Oct-19 | |
| Oct-08 | |
| Oct-01 | |
| Sep-23 | |
| Sep-23 | |
| Sep-22 | |
| Sep-02 | |
| Aug-12 | |
| Aug-05 | |
| Jun-17 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite